Verge Genomics has rebranded as Verge Labs and pivoted from drug development to providing AI-driven data services for target identification, patient selection, and biomarker prediction in neurology after its ALS drug candidate failed in clinical trials.
Merck has entered a multi-target drug discovery collaboration with Protillion Biosciences, investing up to $510 million in milestone payments tied to using Protillion's large-scale data generation platform and AI for protein design to develop a suite of novel biologic therapies.
Digital dermatology is moving deeper into automated and assisted AI terrain through high-fidelity skin digital twins and AI tools that integrate multi-scale omics data, real-time physiological parameters, and generative AI to enable personalized, precise diagnosis, treatment, and drug-response simulation.
Sources:
Verge Genomics Rebrands as Verge Labs Following ALS Drug Trial ...
Merck adds to biopharma's AI agenda with up to $510M+ Protillion ...
Dermatology AI 2.0: A Paradigm Shift Towards Causal Inference ...
Verge Labs turns AI drug discovery into a biology-data pivot
Merck's New AI Partnership Reveals Drug Discovery's Biggest Bottleneck
Frontiers | Principles, applications, and future of artificial intelligence in dermatology
Verge drops sole clinical candidate in return to AI roots
Merck, Protillion Launch AI Drug Discovery Collaboration with Up-to ...
AI and Digital Tools in Dermatology: Addressing Access and ...
The Biotech Edge #113: AI-drug Discovery Pivot After Clinical Failure
'Deep fake' protein designed with artificial intelligence will target ...
Machine learning for precision dermatology: Advances, opportunities, and outlook
Verge Labs' AI model solves patient data problems for neurology ...
Verge Genomics Shifts Strategy to AI-Driven Drug Discovery - LinkedIn